Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Recent & Breaking News (NDAQ:IMNN)

Imunon Reports Partial Results from Ongoing Non-human Primate Study

GlobeNewswire October 3, 2022

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

GlobeNewswire September 29, 2022

IMUNON to Present at Chardan's 6th Annual Genetic Medicines Conference

GlobeNewswire September 27, 2022

Celsion Corporation Announces Company Name Change to Imunon, Inc.

GlobeNewswire September 19, 2022

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

GlobeNewswire September 15, 2022

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

GlobeNewswire September 12, 2022

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 7, 2022

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

GlobeNewswire September 1, 2022

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 15, 2022

Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

GlobeNewswire August 8, 2022

Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

GlobeNewswire July 19, 2022

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

GlobeNewswire July 19, 2022

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

GlobeNewswire June 21, 2022

Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 16, 2022

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

GlobeNewswire May 10, 2022

Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

GlobeNewswire May 9, 2022

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

GlobeNewswire April 21, 2022

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

GlobeNewswire April 14, 2022

Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

GlobeNewswire April 12, 2022

Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire April 8, 2022